US gene sequencing company Illumina’s plan to sell cancer diagnostic test maker Grail got the green light from EU antitrust regulators on Friday after blocking the deal two years ago. The company said it had reached an agreement with the European Commission on specific options for the sale, but the method has yet to be finalised.